



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers / Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antonucci D; Gensini GF; Abbate R. - In: PLATELETS. - ISSN 0953-7104. - STAMPA. - 23:(2012), pp. 586-593. [10.3109/09537104.2012.658106]

Availability:

This version is available at: 2158/606760 since: 2016-02-04T15:12:31Z

Published version:

DOI: 10.3109/09537104.2012.658106

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

(Article begins on next page)

ORIGINAL ARTICLE

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers

ROSSELLA MARCUCCI^{1,2}, BETTI GIUSTI^{1,2}, RITA PANICCIA^{1,2},
ANNA MARIA GORI^{1,2}, CLAUDIA SARACINI¹, SERAFINA VALENTE²,
CRISTINA GIGLIOLI², GUIDO PARODI², DAVID ANTONIUCCI²,
GIAN FRANCO GENSINI^{1,2,3}, & ROSANNA ABBATE^{1,2}

¹Department of Medical and Surgical Critical Care, Centre for the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies, University of Florence, Florence, Italy, ²Department of Heart and Vessels, Azienda Ospedaliero, Universitaria Careggi, Florence, Italy, and ³Centro S. Maria agli Ulivi, Fondazione Don Carlo Gnocchi Onlus IRCCS, Impruneta, Florence, Italy

Abstract

High on-treatment platelet reactivity (HPR) by ADP, which primarily reflects the effect of thienopyridines, has been found to be an independent predictor of ischemic events in patients with acute coronary syndrome (ACS) on dual antiplatelet therapy. CYP2C19*2 is associated with HPR by ADP. The aim of our study was to evaluate if high on-clopidogrel platelet reactivity (HPR) by ADP is associated with an increased risk of major adverse coronary events (MACE) after ACS independent of CYP2C19*2 allele, i.e. whether genotyping patients for CYP2C19*2 polymorphism is sufficient to identify those to be switched to novel antiplatelets. A total of 1187 patients were included (CYP2C19 *1/*1 $n=892$; *1/*2 $n=264$; *2/*2 $n=31$); 76 MACE (CV death and non-fatal MI) were recorded in non-carriers of CYP2C19*2 (8.5%) and 39 in carriers of CYP2C19*2 (13.2%). At the landmark analysis in the first 6 months, HPR by ADP and CYP2C19*2 allele were both significantly and independently associated with MACE [HPR by ADP: HR = 2.0 (95% CI 1.2–3.4), $p=0.01$; CYP2C19*2 allele: HR = 2.3 (95% CI 1.3–3.9), $p=0.003$]. At the landmark analysis from 7 to 12 months, only HPR by ADP remained significantly associated with the risk of MACE [HPR by ADP: HR = 2.7 (95% CI 1.4–5.3), $p=0.003$; CYP2C19*2: HR = 0.8 (95% CI 0.2–1.1), $p=ns$]. CYP2C19*2 allele and HPR by ADP are both independently associated with an increased risk of MACE in the first 6 months after ACS. HPR by ADP is associated with an increased risk until 12 months of follow-up. Therefore, both phenotype and genotype are clinically relevant for the evaluation of the antiplatelet effect of clopidogrel and for the prognostic stratification of ACS patients.

Keywords: High on-treatment platelet reactivity, cardiovascular death, non-fatal myocardial infarction, clopidogrel, CYP2C19*2 polymorphism, acute coronary syndrome

Introduction

High on-treatment platelet reactivity (HPR) by ADP, which primarily reflects the effect of thienopyridines, has been found to be an independent predictor of ischemic events in patients with acute coronary syndrome (ACS) on dual antiplatelet therapy [1–13]. Clopidogrel is a prodrug and, among the different CYP450 isoenzymes involved in its metabolism, CYP2C19 has an important role in its conversion to the active metabolite [14]. Recently, a single nucleotide polymorphism (CYP2C19*2) has

been associated with the inactivation of the enzyme and an impaired metabolism of clopidogrel [14]. The CYP2C19*2 loss-of-function polymorphism is a G681A nucleotide substitution that introduces a splicing defect resulting in a truncated, non-functional protein responsible for the poor metabolizer phenotype [15]. Different groups have contemporarily demonstrated that CYP2C19*2 is associated with HPR by ADP and is a *per se* determinant of the occurrence of major adverse cardiac events (MACE) in percutaneous coronary intervention (PCI) patients on clopidogrel treatment [16–23].

Correspondence: R. Marcucci, Department of Medical and Surgical Critical Care, Centre for the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies, University of Florence, Viale Morgagni 85, Florence 50134, Italy. Tel: 39 055 7949420. Fax: 390 5579 49418. E-mail: rossella.marcucci@unifi.it

(received 24 October 2011; revised 5 January 2012; accepted 12 January 2012)

On the other hand, available data demonstrate that HPR by ADP is associated with clinical and biological characteristics, such as advanced age, diabetes, cardiac failure, the entity of platelet turnover and of inflammatory state [24–26].

Searching for a good tool to identify patients at high risk of recurrences who might need the new, more potent, antiplatelet agents such as prasugrel and ticagrelor, clinicians have the possibility to investigate the phenotype – HPR by ADP – or genotype – CYP2C19*2 polymorphism. The utility of genetic tests to identify differences in CYP2C19 function has been highlighted by the ‘boxed warning’ issued of the Food and Drug Administration advising healthcare professionals to consider use of other antiplatelet medications or alternative dosing strategies for clopidogrel in these patients [27].

The aim of our study was to evaluate if HPR by ADP is associated with MACE even in the absence of CYP2C19*2 allele, i.e. whether genotyping patients for CYP2C19*2 polymorphism is sufficient to identify those with platelet hyperreactivity to be switched to novel antiplatelet drugs.

Materials and methods

Study population

Patients with ACS who underwent PCI and with an anticipated non-adherence to dual antiplatelet treatment for at least 6 months were considered eligible for the study. Informed written consent was obtained from all patients, and the study was approved by the local Ethical Review Board.

PCI and antiplatelet management

All interventions were performed according to the current standard guidelines, and the type of stent implanted and the use of IIb/IIIa inhibitors were at the discretion of the operator. All patients received one clopidogrel loading dose of 600 mg followed by a daily dose of 75 mg. All patients received unfractionated heparin 70 IU/Kg during the procedure and acetylsalicylic acid i.v. 500 mg followed by a daily dose of 100–325 mg by oral route according to the current guidelines for PCI.

CYP2C19*2 polymorphism

Genomic DNA was extracted from whole blood specimens with the use of GeneCatcher™ kit (Invitrogen) automated on the Tecan® Freedom EVO® platform (Tecan) according to the manufacturers’ recommendations. Genotyping for *2 variant of CYP2C19 (rs4244285) was performed with the use of an allelic discrimination assay and the detection system – ABI prism 7900HT Sequence

Detection System (Applied Biosystems). Allele definition follows the nomenclature of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (www.cypalleles.ki.se).

Platelet reactivity assessment

Venous blood samples anticoagulated with 0.109 M sodium citrate (ratio 9:1) were taken from each patient within 24 h from 600 mg clopidogrel loading. For patients receiving in the catheterization laboratory both the loading dose of clopidogrel and a IIb/IIIa inhibitor, blood samples were obtained 6 days after while the patients were on the 75 mg maintenance dose of clopidogrel.

Platelet-rich plasma, obtained by centrifuging whole blood for 10 min at 200 g, was stimulated with 10 µmol ADP (Mascia Brunelli, Milan, Italy) and aggregation was assessed using a AACT 4 light transmission aggregometer (LTA; Helena Laboratories, Milan, Italy) as previously reported [28].

Data collection and follow-up

All data were prospectively collected and entered in a central database. Clinical follow-up information was obtained by contacting all patients at 12 months, and source documents of potential events were obtained.

Endpoints: (1) cardiovascular (CV) death, defined as death in the presence of ACS, significant cardiac arrhythmia or refractory cardiac heart failure; (2) non-fatal myocardial infarction (MI) (a rise in serum troponin I and/or an increase in creatine kinase MB isoenzyme at least twice the upper normal limits with at least one of the following: acute onset of prolonged (≥ 20 min) typical ischemic chest pain; ST-segment elevation of at least 1 mm in two or more contiguous electrocardiographic leads or ST-depression of ≥ 0.5 mm in ≥ 2 contiguous leads).

Statistical analysis

Continuous variables are presented as median (range) or mean and SD as appropriate. Categorical data are reported as frequencies. Differences in continuous variables were compared by Student’s *t*-test or Mann–Whitney *U* test, as appropriate. Dichotomous variables were compared by χ^2 test or Fisher’s Exact test, as appropriate.

A receiver operating characteristic (ROC) curve analysis was used to determine the ability of 10 µmol ADP to distinguish between patients with and without post-discharge events after PCI. Cumulative survival curves for both patients with and without HPR (as defined by 10 µmol ADP LTA $\geq 55\%$ [29]) were constructed by the Kaplan–Meier (KM) method in patients who are carriers and

non-carriers of CYP2C19*2 allele. A landmark analysis was computed by the KM method for CV death and non-fatal MI from 0 to 6 months and from 7 to 12 months. We selected the 6-month point as a landmark according to the prespecified exclusion criterion of anticipated non-adherence to dual antiplatelet treatment for at least 6 months. Univariate and multivariate regression analyses were used, respectively, to identify risk factors for clinical end points and to adjust for potential confounders (CV risk factors, renal failure, left ventricular ejection fraction (LVEF) <40%, multi-vessel disease, total stent length, bifurcation lesions, number of lesions treated and type of stent (BMS or DES), use of GpIIb/IIIa inhibitors and aspirin dosage). McNamar test was used to compare specificity between different aggregometry tests. A significant level was defined when $p < 0.05$. All analysis was performed using SPSS 10.0 (SPSS Inc., Chicago, IL).

Results

A total of 1218 patients with ACS were recruited. Among these patients, 1187 were included in this analysis, while 31 were excluded for the following reasons: anticipated non-adherence to dual antiplatelet treatment, refusal to participate and non-availability of platelet function tests because of thrombocytopenia (Figure 1); 1187 (882 M/305 F) patients with ACS undergoing PCI with stent implantation were included. Genotype distribution of CYP2C19*2 polymorphism was as follows: *1/*1

$n = 892$; *1/*2 $n = 264$; and *2/*2 $n = 31$ (Hardy-Weinberg equilibrium: $\chi^2 = 2.095$, $p = 0.35$). As expected, LTA by 10 μmol ADP was significantly higher in patients who are carriers of *2 allele with respect to the others: $52.5\% \pm 19.9\%$ vs. $46.8\% \pm 21.7\%$, $p < 0.0001$.

Baseline characteristics are given in Tables I and II. The 1-year follow-up rate was 100%. One hundred and fifteen MACE were recorded: 76 events in non-carriers of CYP2C19*2 (8.5%) and 39 events in carriers of CYP2C19*2 (13.2%). Ten micromol ADP LTA values were significantly higher in patients with the subsequent occurrence of CV death and non-fatal MI in both groups (Tables I and II). Clinical characteristics according to the occurrence of CV deaths and non-fatal MI in carriers and




Figure 1. Study flow.

Table I. Clinical characteristics of patients investigated – non-carriers of CYP2C19*2.

| | Overall group ($n = 892$) | 12-month follow-up MACE ($n = 76$) | 12-month follow-up No MACE ($n = 816$) | p^a |
|--------------------------------------|--------------------------------|-----------------------------------------|---------------------------------------------|-------|
| Age, years | 69 (32–93) | 69 (52–90) | 69 (32–93) | 0.006 |
| Male gender, n (%) | 672 (75.3) | 54 (71) | 618 (75.7) | 0.2 |
| Diabetes, n (%) | 219 (24.6) | 21 (27.6) | 198 (24.3) | 0.1 |
| Smoking, n (%) | 327 (36.7) | 29 (38.2) | 298 (36.5) | 0.3 |
| Hypertension, n (%) | 580 (65.0) | 48 (63.2) | 532 (65.2) | 0.4 |
| Dyslipidemia, n (%) | 483 (54.1) | 41 (53.9) | 442 (54.2) | 0.4 |
| LVEF <40%, n (%) | 233 (36.1) | 24 (31.6) | 209 (25.6) | 0.01 |
| Renal failure ^b , n (%) | 80 (9.0) | 7 (9.2) | 73 (8.9) | 0.4 |
| STEMI, n (%) | 318 (35.7) | 29 (38.1) | 289 (35.4) | 0.4 |
| ACE-inhibitors, n (%) | 598 (67.0) | 52 (68.4) | 554 (67.9) | 0.9 |
| Beta-blockers, n (%) | 357 (40.0) | 31 (40.7) | 334 (40.9) | 0.8 |
| Statins, n (%) | 562 (63) | 48 (63.1) | 514 (62.9) | 0.8 |
| Pump inhibitors, n (%) | 829 (93) | 70 (92.1) | 759 (93) | 0.8 |
| Glycoprotein IIb/IIIa, n (%) | 357 (40) | 29 (38.1) | 326 (39.9) | 0.5 |
| Vessels treated, n | 1328 | 155 | 1173 | – |
| Drug eluting stent, n (%) | 156 (17.5) | 16 (21) | 142 (17.4) | 0.2 |
| Bifurcation lesion, n (%) | 366 (41) | 31 (40.7) | 335 (41) | 0.6 |
| Total stent length (mm) | 34.5 ± 22.3 | 33.6 ± 22.6 | 34.5 ± 22.3 | 0.4 |
| LTA by 10 μmol ADP | 46.8 ± 21.7 | 55.8 ± 21.4 | 45.9 ± 21.5 | 0.001 |

Notes: MACE = CV death and non-fatal MI.

^aMACE vs. no MACE and ^brenal insufficiency defined by creatinine levels above 2.0 mg/dl.

Table II. Clinical characteristics of patients investigated – carriers of CYP2C19*2 (*1/*2 + *2/*2).

| | Overall group (<i>n</i> = 295) | 12-month follow-up MACE (<i>n</i> = 39) | 12-month follow-up No MACE (<i>n</i> = 256) | <i>p</i> ^a |
|-------------------------------------------|------------------------------------|---------------------------------------------|-------------------------------------------------|-----------------------|
| Age, years | 69 (29–94) | 71 (29–85) | 69 (36–94) | 0.001 |
| Male gender, <i>n</i> (%) | 216 (73.2) | 30 (76.9) | 183 (71.4) | 0.2 |
| Diabetes, <i>n</i> (%) | 66 (22.3) | 13 (33.3) | 53 (20.7) | 0.1 |
| Smoking, <i>n</i> (%) | 108 (36.6) | 16 (41) | 92 (35.9) | 0.3 |
| Hypertension, <i>n</i> (%) | 197 (66.7) | 28 (71.7) | 169 (66) | 0.4 |
| Dyslipidemia, <i>n</i> (%) | 163 (55.2) | 20 (51.2) | 143 (55.8) | 0.4 |
| LVEF <40%, <i>n</i> (%) | 75 (25.4) | 12 (30.1) | 63 (24.6) | 0.05 |
| Renal failure ^b , <i>n</i> (%) | 26 (8.8) | 3 (7.6) | 23 (8.9) | 0.4 |
| STEMI, <i>n</i> (%) | 101 (34.2) | 13 (33.3) | 88 (34.4) | 0.2 |
| ACE-inhibitors, <i>n</i> (%) | 195 (66) | 27 (69.2) | 168 (65.6) | 0.8 |
| Beta-blockers, <i>n</i> (%) | 114 (38.6) | 16 (41) | 98 (38.2) | 0.5 |
| Statins, <i>n</i> (%) | 191 (64.7) | 25 (64.1) | 166 (64.8) | 0.4 |
| Pump inhibitors, <i>n</i> (%) | 285 (96.6) | 36 (92.3) | 249 (97.2) | 0.3 |
| Glycoprotein IIb/IIIa, <i>n</i> (%) | 115 (38.9) | 15 (38.4) | 100 (39.0) | 0.8 |
| Vessels treated, <i>n</i> | 439 | 79 | 360 | – |
| Drug eluting stent, <i>n</i> (%) | 54 (18.3) | 8 (20.5) | 46 (17.9) | 0.1 |
| Bifurcation lesion, <i>n</i> (%) | 94 (31.8) | 14 (35.8) | 80 (31.2) | 0.8 |
| Total stent length (mm) | 35.6 ± 26.9 | 33.6 ± 22.6 | 34.5 ± 22.3 | 0.4 |
| LTA by 10 μmol ADP | 52.5 ± 19.9 | 61.6 ± 17.6 | 51.1 ± 19.9 | 0.001 |

Note: As in notes of Table I.




Figure 2. ROC curve for LTA by 10 μmol ADP.




Figure 3. KM survival curves for CV death and non-fatal MI.

non-carriers of CYP2C19*2 are reported in Tables I and II.

ROC curve analysis demonstrated that 10 μ mol ADP LTA was able to distinguish between patients with and without subsequent CV death and non-fatal MI at 12-month follow-up both in *carriers* and *non-carriers* of CYP2C19*2 (Area under the curve 0.66 (0.57–0.75), $p < 0.001$ and 0.64 (0.57–0.71), $p < 0.001$, respectively) (Figure 2).

The event-free survival curves for CV death and non-fatal MI according to *2 allele carriers vs. non-carriers are shown in Figure 3(b) (10 μ mol ADP LTA in CYP2C19 *1/*1 = 46.8% \pm 21.7%; *1/*2 = 51.3% \pm 19.6%; and *2/*2 = 63.2% \pm 19.3%). In Figure 3(a), (c), and (d), KM curves according to HPR vs. non-HPR both in carriers and non-carriers of CYP2C19*2 allele are reported.

The landmark analysis (0–6 months and 7–12 months) showed that the differences between HPR and non-HPR groups in CV death and non-fatal MI emerged both in the short-term follow-up (Figure 4) as well as later on (Figure 5). On the other hand, carriers of CYP2C19*2 were associated with a

significant higher risk until 6 months (Figure 4), but not between 6 and 12 months (Figure 5).

Patients with LTA by ADP $\geq 55\%$, which we previously demonstrated to be the optimal cut-off for detection of ischemic recurrences [29], were significantly older, more likely to be female, diabetic and with reduced LVEF with respect to patients without RPR (Table III).

At the land mark analysis in the first 6 months (0–6), HPR by ADP and CYP2C19*2 allele were both significantly and independently associated with a higher risk of CV death and non-fatal MI after adjustment for CV risk factors, renal failure, reduced ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent and use of GpIIb/IIIa inhibitors [HPR by ADP: HR = 2.0 (95% CI 1.2–3.4), $p = 0.01$; CYP2C19*2 allele: HR = 2.3 (95% CI 1.3–3.9), $p = 0.003$]. The presence of both – HPR by ADP and CYP2C19*2 allele – was associated with a higher risk: HR = 2.7 (1.5–5.1), $p < 0.001$.

At the land mark analysis from 7 to 12 months, only HPR by ADP remained significantly associated




Figure 4. KM landmark analysis survival curves for CV death and non-fatal MI (0–6 months).

with the risk of MACE at the Cox regression analysis adjusted for CV risk factors, renal failure, reduced ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent and use of GpIIb/IIIa inhibitors [HPR by ADP: HR = 2.7 (95% CI 1.4–5.3), $p = 0.003$; CYP2C19*2: HR = 0.8 (95% CI 0.2–1.1), $p = \text{ns}$].

Discussion

In this analysis, we demonstrate that HPR by ADP is a risk factor for clinical recurrences in ACS patients on dual antiplatelet treatment, even in the absence of CYP2C19*2 allele.

The history of the ‘resistance’ to clopidogrel moves from the studies which found an association between HPR by ADP and risk of vascular complications, i.e. stent thrombosis, CV death and non-fatal MI [1–16]. Subsequently, different researchers, including our group, studied the possible genetic determinants of response to clopidogrel focusing on the presence of polymorphisms in genes

coding for CYP450 enzymes [17]. It has been detected that CYP2C19*2 polymorphism is associated with HPR by ADP and it is *per se* associated with vascular risk [18–24]. Furthermore, we found that both HPR by ADP and CYP2C19*2 polymorphism were independently associated with the occurrence of stent thrombosis and CV death [23] at a 6-month follow-up.

Indeed, both genotype – CYP2C19*2 allele – and phenotype – HPR by ADP – are available in order to identify patients who might need a more potent platelet inhibition, potentially by the new antiplatelet drugs such as prasugrel or ticagrelor.

The question to be answered is if the issue of platelet hyperreactivity on treatment is a phenomenon to be restricted, in the clinical practice, to the problem of the metabolism of clopidogrel. The recent ‘boxed warning’ of FDA underlines the importance of CYP2C19*2 polymorphism for the choice of alternative drugs to clopidogrel [27].

For this purpose, we have decided to evaluate the risk of clinical recurrences according to HPR by ADP in carriers and non-carriers of




Figure 5. KM landmark analysis survival curves for CV death and non-fatal MI (7–12 months).

Table III. Clinical characteristics according to HPR by ADP (10 μ mol ADP LTA \geq 55%).

| | Non-carriers of CYP2C19*2 | | <i>p</i> | Carriers of CYP2C19*2 | | <i>p</i> |
|-------------------------------------------|------------------------------|---------------------------------|----------|------------------------------|---------------------------------|----------|
| | HPR by ADP (<i>n</i> = 342) | No HPR by ADP (<i>n</i> = 550) | | HPR by ADP (<i>n</i> = 144) | No HPR by ADP (<i>n</i> = 151) | |
| Age, years | 69 (46–93) | 69 (32–93) | <0.05 | 73 (29–90) | 67 (36–94) | <0.005 |
| Male gender, <i>n</i> (%) | 250 (73) | 422 (76.7) | <0.05 | 104 (72.2) | 112 (74.1) | <0.05 |
| Diabetes, <i>n</i> (%) | 90 (26.3) | 129 (23.5) | <0.001 | 40 (27.7) | 26 (17.2) | <0.0001 |
| Smoking, <i>n</i> (%) | 120 (35.1) | 207 (37.6) | 0.4 | 55 (38.2) | 53 (35.1) | 0.04 |
| Hypertension, <i>n</i> (%) | 240 (70.2) | 340 (61.8) | 0.5 | 98 (68) | 99 (65.5) | 0.3 |
| Dyslipidemia, <i>n</i> (%) | 171 (50) | 312 (56.7) | 0.2 | 75 (52.1) | 88 (58.3) | 0.4 |
| LVEF <40%, <i>n</i> (%) | 91 (26.6) | 142 (25.8) | <0.001 | 38 (26.4) | 37 (24.5) | <0.05 |
| Renal failure ^a , <i>n</i> (%) | 23 (6.7) | 57 (10.4) | 0.4 | 10 (6.9) | 16 (10.6) | 0.4 |
| STEMI, <i>n</i> (%) | 104 (30.4) | 176 (32) | <0.001 | 36 (25) | 65 (43) | <0.001 |
| ACE-inhibitors, <i>n</i> (%) | 229 (66.9) | 374 (68) | 0.3 | 96 (66.6) | 99 (65.6) | 0.2 |
| Beta-blockers, <i>n</i> (%) | 140 (40.9) | 225 (40.9) | 0.3 | 59 (40.9) | 55 (36.4) | 0.5 |
| Statins, <i>n</i> (%) | 215 (62.8) | 346 (62.9) | 0.1 | 91 (63.2) | 100 (66.2) | 0.09 |
| Pump inhibitors, <i>n</i> (%) | 318 (92.9) | 511 (92.9) | 0.2 | 136 (94.4) | 149 (98.6) | 0.07 |
| Glycoprotein IIb/IIIa, <i>n</i> (%) | 140 (40.9) | 214 (38.9) | 0.9 | 59 (40.9) | 56 (37) | 0.8 |
| Vessels treated, <i>n</i> | 514 | 814 | – | 216 | 223 | – |
| Drug eluting stent, <i>n</i> (%) | 74 (21.6) | 83 (15) | <0.01 | 32 (22.2) | 22 (14.5) | <0.005 |
| Bifurcation lesion, <i>n</i> (%) | 145 (42.3) | 221 (40.2) | 0.2 | 52 (36.1) | 42 (27.8) | 0.2 |
| Total stent length (mm) | 35.5 \pm 21.6 | 33.8 \pm 22.7 | <0.01 | 39.1 \pm 29.9 | 31.9 \pm 23.5 | <0.001 |

CYP2C19*2 allele. If the problem of HPR by ADP is only associated with clopidogrel metabolism, we should find that HPR in the absence of CYP2C19*2 allele is not associated with an increased risk of recurrences.

Conversely, our data demonstrate that the presence of CYP2C19*2 allele confers a higher risk in the first months after the acute event, and HPR by ADP also later on. These data are in line with those obtained in the meta-analysis by Mega et al. [23], in which the authors failed to find a significant association between CYP2C19*2 allele and MACE in landmark analyses from 31 days until the end of follow-up.

HPR on treatment is a complex phenomenon for which pharmacogenetic accounts only in part.

In other words, these findings demonstrate that the entity of platelet inhibition on treatment is a prognostic factor in ACS patients, independent of the variability associated with clopidogrel metabolism.

Accordingly, both genotype and phenotype are clinically relevant:

- (1) Genotyping patients for CYP2C19*2 allele allows us to identify patients who immediately need an alternative drug to clopidogrel, independent of the clinical characteristics and clinical manifestation of the disease.
- (2) Phenotyping patients for the entity of platelet inhibition by ADP allows us to obtain an information about a factor which maintains its prognostic role until 12 months after the acute event. Available evidence tells us that we have to obtain a platelet inhibition which might be around 55% to reduce the risk of ischemic recurrences.

The main limitation of our study is the lack of information on the occurrence of stent thrombosis.

Furthermore, this study includes only a genetic determinant of HPR by ADP. A number of genetic polymorphisms are under evaluation to determine their possible role in affecting the entity of platelet inhibition on treatment. Nevertheless, till now, only CYP2C19*2 allele has been consistently associated with the intermediate phenotype 'HPR by ADP' and with a significantly increased vascular risk [18–23].

Furthermore, we are aware that platelet reactivity at the time of ACS may be affected by a number of clinical and laboratory parameters, including the high level of the inflammatory state and the increased platelet turnover [24–26]. Consequently, a percentage of patients with platelet hyperreactivity in the acute state might subsequently return to an adequate platelet inhibition. The issue of the durability of HPR remains to be solved by ad hoc studies. Nevertheless,

our results underline the concept that antiplatelet therapy, driven by the determination of the phenotype HPR, might be modulated not only with respect to the type of the disease, but also with respect to the different phases of the same disease (acute vs. chronic phase) suggesting the need of checking the persistence of HPR over the time.

In conclusion, we found that HPR by ADP is associated with an increased risk of 12-month follow-up MACE even in the absence of the genetic polymorphism – CYP2C19*2 – associated with a reduced metabolism of clopidogrel. Therefore, both phenotype and genotype are clinically relevant for the evaluation of the antiplatelet effect of clopidogrel and for the prognostic stratification of ACS patients.

Disclosures: All authors have no conflict of interests.

Funding: Grant to FIORGEN Foundation by Ente Cassa di Risparmio Florence, Italy.

References

1. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. *Thromb Haemost* 2010;2:103–110.
2. Buonomici PG, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antonucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. *J Am Coll Cardiol* 2007;24:2312–2317.
3. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. *Eur Heart J* 2008;29:992–1000.
4. Sibbing D, Braun S, Jawansky S, Vogt W, Mehili J, Schömig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. *Thromb Haemost* 2008;99:121–126.
5. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost*. 2005;3:85–92.
6. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. *Thromb Haemost*. 2007;98:838–843.
7. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. *J Am Coll Cardiol*. 2008;51:1404–1411.

8. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici PG, Antonucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-month follow-up. *Circulation* 2009;119:237–242.
9. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici PG, Gensini GF, Vergara R, Abbate R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. *J Am Coll Cardiol* 2008;52:734–739.
10. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. *J Am Coll Cardiol* 2005;45:1392–1396.
11. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Bañuelos C, Hernández-Antolín R, Escaned J, Moreno R, Alfonso F, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. *Eur Heart J* 2004;25:1903–1910.
12. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. *J Thromb Haemost* 2008;6:54–61.
13. Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. *Circulation* 2009;120:2214–2221.
14. Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19*2 loss-of-function polymorphism to the occurrence of stent thrombosis. *Expert Opin Drug Metab Toxicol* 2010;6:393–407.
15. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antonucci D, Abbate R, Gensini GF. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. *Pharmacogenet Genomics* 2007;17:1057–1064.
16. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. *J Am Coll Cardiol* 2008;51:1925–1934.
17. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* 2009;360:363–375.
18. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* 2009;360: 354–362.
19. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. *Lancet* 2009;373:309–317.
20. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antonucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. *Am J Cardiol* 2009;103:806–811.
21. Sibbing D, Stegheer J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 2009;30:916–922.
22. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2c19*2 polymorphism and cardiovascular recurrences in aptients taking clopidogrel: A meta-analysis. *Pharmacogenetics J* 2010;11(3):199–206.
23. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CC, Danchin N, Giusti B, Gurbel P, et al. Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. *JAMA* 2010;304:1821–1830.
24. Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, Gensini GF, Abbate R. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. *Atherosclerosis* 2009;202:255–262.
25. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. *Thromb Haemost* 2008;99:930–935.
26. Marcucci R, Gori AM, Paniccia R, Giglioli C, Buonamici P, Antonucci D, Gensini GF, Abbate R. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. *Atherosclerosis* 2007;195:217–223.
27. US Food and Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Silver Spring, MD: US Food and Drug Administration. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm> (accessed 24 March 2010).
28. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antonucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. *J Thromb Haemost* 2007;5:1839–1847.
29. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici PG, Antonucci D, Abbate R, Gensini GF. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow up cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. *Thromb Haemost* 2010;104:279–286.